[go: up one dir, main page]

CA2585561A1 - Resultat de groupe esr1, pgr, bcl2 et scube2 comme indicateurs de pronostic de cancer du sein et de prediction de la reponse au traitement - Google Patents

Resultat de groupe esr1, pgr, bcl2 et scube2 comme indicateurs de pronostic de cancer du sein et de prediction de la reponse au traitement Download PDF

Info

Publication number
CA2585561A1
CA2585561A1 CA002585561A CA2585561A CA2585561A1 CA 2585561 A1 CA2585561 A1 CA 2585561A1 CA 002585561 A CA002585561 A CA 002585561A CA 2585561 A CA2585561 A CA 2585561A CA 2585561 A1 CA2585561 A1 CA 2585561A1
Authority
CA
Canada
Prior art keywords
expression
patient
esr1
gene
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002585561A
Other languages
English (en)
Other versions
CA2585561C (fr
Inventor
Joffre B. Baker
John L. Bryant
Soonmyung Paik
Steven Shak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genomic Health Inc
NSABP Foundation Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2585561A1 publication Critical patent/CA2585561A1/fr
Application granted granted Critical
Publication of CA2585561C publication Critical patent/CA2585561C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

La présente invention concerne des indicateurs moléculaires quantitatifs qui peuvent guider des décisions cliniques dans le cancer du sein, tels que le cancer du sein positif-récepteur oestrogènes (ESR1), négatif- ganglion lymphatique. Cette invention concerne en particulier certains gènes, dont l'expression modifiée indique la vraisemblance d'une récurrence d'un cancer du sein traité par chirurgie chez des patientes qui ne sont pas traitées avec un agent thérapeutique dans le traitement adjuvant. Par ailleurs, cette invention concerne l'utilisation de mesure quantitative de l'expression de certains gènes, notamment du gène ESR1, qui donne une mesure sous forme de variable continue, afin de déterminer (a) la vraisemblance d'une réponse bénéfique à cet agent thérapeutique anti-oestrogène, tel que le tamoxifène et, (b) l'importance potentielle de la réponse bénéfique à la chimiothérapie.
CA2585561A 2004-11-05 2005-11-04 Resultat de groupe esr1, pgr, bcl2 et scube2 comme indicateurs de pronostic de cancer du sein et de prediction de la reponse au traitement Expired - Lifetime CA2585561C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62544204P 2004-11-05 2004-11-05
US60/625,442 2004-11-05
PCT/US2005/039970 WO2006052731A2 (fr) 2004-11-05 2005-11-04 Indicateurs moleculaires de pronostic de cancer du sein et prediction de reponse de traitement

Publications (2)

Publication Number Publication Date
CA2585561A1 true CA2585561A1 (fr) 2006-05-18
CA2585561C CA2585561C (fr) 2018-07-17

Family

ID=36337021

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2585561A Expired - Lifetime CA2585561C (fr) 2004-11-05 2005-11-04 Resultat de groupe esr1, pgr, bcl2 et scube2 comme indicateurs de pronostic de cancer du sein et de prediction de la reponse au traitement

Country Status (10)

Country Link
US (2) US7622251B2 (fr)
EP (1) EP1815014B1 (fr)
JP (1) JP4939425B2 (fr)
AT (1) ATE550440T1 (fr)
AU (1) AU2005304878B2 (fr)
CA (1) CA2585561C (fr)
DK (1) DK1815014T3 (fr)
ES (1) ES2384107T3 (fr)
IL (1) IL182930A (fr)
WO (1) WO2006052731A2 (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261368A1 (fr) * 2002-03-13 2010-12-15 Genomic Health, Inc. Profilage de l'expression génétique dans des tissus de tumeurs prélevées par biopsie
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2005039382A2 (fr) * 2003-06-24 2005-05-06 Genomic Health Prediction de probabilite de la recurrence d'un cancer
CA2848463A1 (fr) 2004-04-09 2005-10-27 Genomic Health, Inc. Marqueurs d'expression genique permettant de predire la reponse a la chimiotherapie
CA3061785A1 (fr) * 2004-11-05 2006-05-18 Genomic Health, Inc. Prediction de reaction a la chimiotherapie au moyen de marqueurs d'expression genique
US20060134243A1 (en) * 2004-12-17 2006-06-22 Bionovo, Inc. Method of using extracts of epimedium species
US7482029B2 (en) 2005-04-01 2009-01-27 Bionovo, Inc. Composition for treatment of menopause
EP1931802A2 (fr) * 2005-09-09 2008-06-18 The Board of Regents of The University of Texas System Indice calcule d'expression genomique de recepteurs des oestrogenes (er) et genes associes aux er
US7700136B2 (en) * 2005-11-14 2010-04-20 Bionovo, Inc. Scutellaria barbata extract for the treatment of cancer
EP1873258A1 (fr) * 2006-06-26 2008-01-02 Universitätsklinikum Hamburg-Eppendorf Détection de l'amplification de ESR1 dans le cancer du sein
DK2081950T3 (da) * 2006-09-21 2013-06-03 Nuclea Biomarkers Llc Med irinotecanbehandling forbundne ekspressionsprofiler
EP2066805B1 (fr) * 2006-09-27 2016-07-27 Sividon Diagnostics GmbH Procédés pour pronostiquer un cancer du sein
SG142186A1 (en) * 2006-10-20 2008-05-28 Agency Science Tech & Res Breast tumour grading
EP2090588A4 (fr) 2006-10-23 2010-04-07 Neocodex S L Methode de pronostic et/ou de diagnostic in vitro de l'hypersensibilite aux oestrogenes ou a des substances ayant une activite oestrogenique
US8470534B2 (en) * 2006-12-01 2013-06-25 Erik S. Knudsen Methods of predicting resistance or sensitivity to therapies for cancer
WO2008115561A2 (fr) * 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Biomarqueurs et méthodes permettant de déterminer la sensibilité à des agents stabilisant les microtubules
EP1978106A1 (fr) * 2007-04-07 2008-10-08 Universitätsklinikum Hamburg-Eppendorf Amplificateur ayant une protection de sortie, en particulier un amplificateur opérationnel pour une application audio
US20090070138A1 (en) * 2007-05-15 2009-03-12 Jason Langheier Integrated clinical risk assessment system
WO2008145125A1 (fr) * 2007-05-31 2008-12-04 Dako Denmark A/S Procédés d'utilisation des changements du nombre de copies d'esr dans les traitements et les pronostics du cancer du sein
US20090042818A1 (en) * 2007-06-22 2009-02-12 Bionovo, Inc. Liquiritigenin and Derivatives as Selective Estrogen Receptor Beta Agonists
US20080319051A1 (en) * 2007-06-22 2008-12-25 Bionovo, Inc. Liquiritigenin and derivatives as selective estrogen receptor beta agonists
CA2696304A1 (fr) * 2007-08-08 2009-02-12 Bionovo, Inc. Extraits de iligustrum lucidum et leurs utilisations
EP2228457A1 (fr) * 2007-08-16 2010-09-15 Genomic Health, Inc. Marqueurs de l'expression génique du risque récurrent chez des patients atteints de cancer après la chimiothérapie
EP2198296B1 (fr) * 2007-09-05 2015-11-11 Laurentian University Procédé d'utilisation de l'intégrité d'arn tumoral pour mesurer la réponse à la chimiothérapie chez des patients atteints de cancer
US20090068298A1 (en) * 2007-09-07 2009-03-12 Bionovo, Inc. ESTROGENIC EXTRACTS OF Astragalus membranaceus Fisch. Bge. Var. mongolicus Bge. of the Leguminosae Family AND USES THEREOF
JP2010538093A (ja) * 2007-09-07 2010-12-09 バイオノボ・インコーポレーテッド シソ科ファミリーのセイタカナミキソウのエストロゲン性抽出物およびその使用
AU2008296076A1 (en) * 2007-09-07 2009-03-12 Bionovo, Inc. Estrogenic extracts of Pueraria lobata Willd, Ohwi of the Leguminosae family and uses thereof
EP2194998A4 (fr) * 2007-09-07 2012-03-21 Bionovo Inc Extraits strogéniques d'asparagus conchinchinensis (lour.) merr de la famille des liliacées et leurs utilisations
AU2008326429A1 (en) * 2007-11-19 2009-05-28 Bionovo, Inc. Anti-cancer therapy with an extract of scutellaria barbata
JP2011503237A (ja) * 2007-11-19 2011-01-27 バイオノボ・インコーポレーテッド Ｓｃｕｔｅｌｌａｒｉａｂａｒｂａｔａｄ．ｄｏｎの精製抽出物を作製するためのプロセス
US8512961B2 (en) * 2007-11-19 2013-08-20 Bionovo, Inc. Methods of detecting and treatment of cancers using Scutellaria barbata extract
AU2008326431A1 (en) * 2007-11-19 2009-05-28 Bionovo, Inc. Scutellaria barbata extract and combinations for the treatment of cancer
EP2065473A1 (fr) * 2007-11-28 2009-06-03 Siemens Healthcare Diagnostics GmbH Procédé d'évaluation de pronostic et de prédiction de succès thérapeutique dans un cancer gynécologique
EP2065474A1 (fr) * 2007-11-28 2009-06-03 Siemens Healthcare Diagnostics GmbH Méthode pour le prognostic de la réponse thérapeutique au traitement endocrinien
WO2009068423A2 (fr) 2007-11-30 2009-06-04 Siemens Healthcare Diagnostics Gmbh Procédé de prédiction d'une sensibilité à une thérapie dans des tumeurs de type basales
WO2009095319A1 (fr) * 2008-01-28 2009-08-06 Siemens Healthcare Diagnostics Gmbh Pronostic de cancer par vote majoritaire
US20090258942A1 (en) * 2008-04-14 2009-10-15 Bionovo, Inc. Calycosin and analogs thereof for the treatment of estrogen receptor beta-mediated diseases
WO2009132028A1 (fr) * 2008-04-21 2009-10-29 Complete Genomics, Inc. Structures pour puces de détection d'acides nucléiques
WO2009137534A2 (fr) * 2008-05-06 2009-11-12 Bionovo, Inc. Extraits œstrogéniques utilisés dans le traitement de l’atrophie vaginale et vulvaire
CA2726982A1 (fr) * 2008-06-05 2009-12-10 Bionovo, Inc. Procede de quantification de multiples agents bioactifs provenant de compositions botaniques
WO2009148620A2 (fr) * 2008-06-06 2009-12-10 Bionovo, Inc. Anthraquinones et analogues provenant de rheum palmatum pour le traitement d'états à médiation par le récepteur bêta de l'œstrogène
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
ES2338843B1 (es) * 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
WO2010028187A2 (fr) * 2008-09-03 2010-03-11 Bionovo, Inc. Procédés et compositions destinés au traitement du cancer
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
JP5550060B2 (ja) * 2008-10-03 2014-07-16 独立行政法人産業技術総合研究所 そうか病病原菌種のｐｃｒ定量用試薬キット
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
US20110195995A1 (en) * 2008-10-14 2011-08-11 Wittliff James L Methods of Optimizing Treatment of Estrogen-Receptor Positive Breast Cancers
ES2343996B1 (es) 2008-12-11 2011-06-20 Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz Metodo para la subclasificacion de tumores.
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
JP2012525412A (ja) * 2009-04-28 2012-10-22 バイオノボ・インコーポレーテッド 脂肪蓄積を減少させ、体重減少を誘導する方法
WO2010125117A2 (fr) 2009-04-29 2010-11-04 Ralph Wirtz Procédé permettant d'évaluer un pronostic et de prévoir le succès d'un traitement contre le cancer par détermination des niveaux d'expression d'un récepteur hormonal
WO2010127338A1 (fr) * 2009-05-01 2010-11-04 Nuvera Biosciences, Inc. Indice d'expression génomique du récepteur d'oestrogènes (er) et gènes liés auxdits er
EP2253715A1 (fr) * 2009-05-14 2010-11-24 RWTH Aachen Nouvelles cibles pour la thérapie et/ou le diagnostic du cancer
MX2012011167A (es) 2010-03-31 2013-02-07 Sividon Diagnostics Gmbh Metodo para prediccion de recurrencia de cancer de mama bajo tratamiento endocrino.
EP3812469A1 (fr) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Signatures géniques pour le pronostic du cancer
MX355020B (es) 2010-07-09 2018-04-02 Somalogic Inc Biomarcadores de cancer de pulmon y usos de los mismos.
JP5931874B2 (ja) 2010-08-13 2016-06-08 ソマロジック・インコーポレーテッド 膵癌バイオマーカーおよびその使用
WO2012030840A2 (fr) 2010-08-30 2012-03-08 Myriad Genetics, Inc. Signatures génétiques pour le diagnostic et le pronostic du cancer
RU2486518C1 (ru) * 2012-01-10 2013-06-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт онкологии Сибирского отделения Российской академии медицинских наук (НИИ онкологии СО РАМН) Способ прогнозирования возникновения местных рецидивов в послеоперационном рубце при уницентрическом инвазивном протоковом раке молочной железы у больных с сохраненной менструальной функцией
CA2871195C (fr) 2012-04-24 2023-01-10 Rna Diagnostics Inc. Dosages, methodes et appareil pour l'evaluation de la disruption d'un arn
WO2014078700A1 (fr) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Signatures génétiques utilisées en vue du pronostic d'un cancer
JP6479672B2 (ja) 2012-12-03 2019-03-06 アールエヌエー、ダイアグノスティックス、インコーポレイテッドＲｎａ Ｄｉａｇｎｏｓｔｉｃｓ Ｉｎｃ． 癌における放射線療法に対する応答をモニタリングするための方法およびキット
US20150376714A1 (en) 2013-02-01 2015-12-31 Sividon Diagnostics Gmbh Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer
US10731222B2 (en) 2013-10-04 2020-08-04 Rna Diagnostics Inc. RNA disruption assay for predicting survival
EP2910645A1 (fr) * 2014-02-25 2015-08-26 STRATIFYER Molecular Pathology GmbH Procédés et compositions pour la prédiction de l'efficacité thérapeutique de traitements du cancer et le pronostic du cancer lors d'un traitement à base d'anticorps
EP3143160B1 (fr) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Signatures génétiques utilisées en vue du pronostic d'un cancer
CN104004844A (zh) * 2014-05-28 2014-08-27 杭州美中疾病基因研究院有限公司 乳腺癌21基因联合检测试剂盒及其制备方法
EP3825411A1 (fr) 2014-06-18 2021-05-26 Clear Gene, Inc. Procédés, compositions et dispositifs pour l'analyse rapide de marqueurs biologiques
US10980519B2 (en) 2015-07-14 2021-04-20 Duke University Systems and methods for extracting prognostic image features
US11401558B2 (en) 2015-12-18 2022-08-02 Clear Gene, Inc. Methods, compositions, kits and devices for rapid analysis of biological markers
US12275994B2 (en) * 2017-06-22 2025-04-15 Clear Gene, Inc. Methods and compositions for the analysis of cancer biomarkers
EP3679160A4 (fr) 2017-09-08 2021-05-19 Myriad Genetics, Inc. Procédé d'utilisation de biomarqueurs et de variables cliniques pour prédire l'intérêt d'une chimiothérapie
US12008747B2 (en) * 2019-07-29 2024-06-11 Case Western Reserve University Population-specific prediction of prostate cancer recurrence based on stromal morphology features
CN111500724B (zh) * 2020-04-28 2023-11-21 启程医学科技(山东)有限公司 用于乳腺癌六基因同时检测的引物组与探针组合
WO2023081988A1 (fr) * 2021-11-09 2023-05-19 Coelho Guilherme Portela Méthode de prédiction d'efficacité d'un traitement contre le cancer du sein

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699877A (en) 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
IE56509B1 (en) 1982-11-04 1991-08-28 Univ California Methods for oncogenic detection
USRE35491E (en) 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5015568A (en) 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) * 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5858678A (en) 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
CA2239692C (fr) * 1995-12-18 2008-12-16 Sugen, Inc. Diagnostic et traitement de troubles lies aux aur-1 et aur-2
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US5821082A (en) 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
US6203993B1 (en) * 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US5952178A (en) * 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6143529A (en) * 1996-08-14 2000-11-07 Exact Laboratories, Inc. Methods for improving sensitivity and specificity of screening assays
US6020137A (en) * 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US5861278A (en) * 1996-11-01 1999-01-19 Genetics Institute, Inc. HNF3δ compositions
CA2271783C (fr) * 1996-11-20 2013-04-16 Yale University La survivine, proteine inhibant l'apoptose cellulaire, et sa modulation
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US5830665A (en) * 1997-03-03 1998-11-03 Exact Laboratories, Inc. Contiguous genomic sequence scanning
US6033893A (en) * 1997-06-26 2000-03-07 Incyte Pharmaceuticals, Inc. Human cathepsin
WO1999002714A1 (fr) 1997-07-07 1999-01-21 Abbott Laboratories Reactifs et procedes utilises pour detecter les maladies du sein
US6020135A (en) * 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
CA2330929A1 (fr) 1998-06-06 1999-12-16 Genostic Pharma Limited Sondes permettant de determiner un profil genetique
US6696558B2 (en) * 1998-09-09 2004-02-24 The Burnham Institute Bag proteins and nucleic acid molecules encoding them
AU3246200A (en) 1999-02-25 2000-09-14 Boris Bilynsky Nucleic acid molecules associated with melanoma and thyroid tumors
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US20020039764A1 (en) * 1999-03-12 2002-04-04 Rosen Craig A. Nucleic, acids, proteins, and antibodies
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) * 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6326148B1 (en) 1999-07-12 2001-12-04 The Regents Of The University Of California Detection of copy number changes in colon cancer
US6710170B2 (en) * 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
AU777096B2 (en) 1999-10-06 2004-09-30 Regents Of The University Of California, The Differentially expressed genes associated with Her-2/neu overexpression
EP1686134A3 (fr) 1999-12-01 2006-08-09 Genentech, Inc. Polypeptides transmembranaires et secrétés et les acides nucléiques codant ceux-ci
US6750013B2 (en) 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
US6248535B1 (en) * 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
WO2001051661A2 (fr) 2000-01-13 2001-07-19 Amsterdam Support Diagnostics B.V. Systeme universel d'amplification de l'acide nucleique pour acides nucleiques d'un prelevement
US6322986B1 (en) 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
WO2001055454A1 (fr) 2000-01-28 2001-08-02 Althea Technologies, Inc. Procedes d'analyse de l'expression genique
WO2001055343A1 (fr) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps
AU4592601A (en) 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
WO2001075162A2 (fr) 2000-03-31 2001-10-11 University Of Louisville Research Foundation, Inc. Jeux ordonnes de microechantillons permettant de cribler des genes regulateurs
WO2002000677A1 (fr) 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps
MXPA03000575A (es) 2000-07-21 2004-12-13 Global Genomics Ab Metodos para analisis e identificacion de genes transcritos e impresion dactilar.
AU2001277202A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ras/rerg protein and related reagents and methods of use thereof
WO2002008262A2 (fr) 2000-07-26 2002-01-31 Stanford University Proteines bstp-5 et reactifs apparentes, et leurs procedes d'utilisation
WO2002008260A2 (fr) 2000-07-26 2002-01-31 Stanford University Proteine bstp-ecg1 et reactifs associes et procedes d'utilisation de ceux-ci
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US6582919B2 (en) 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US6602670B2 (en) 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
EP1353947A2 (fr) 2000-12-08 2003-10-22 Ipsogen Caracterisation de l'expression genique des carcinomes primaires du sein a l'aide de reseaux de genes d'interet
WO2002068579A2 (fr) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits tels que des dosages d'acides nucleiques comprenant une majorite d'exons ou de transcrits humains, destines a detecter l'expression et pouvant avoir d'autres applications
WO2002057787A2 (fr) * 2001-01-12 2002-07-25 Yale University Detection de survivine dans les liquides biologiques de patients cancereux
US7776518B2 (en) * 2001-01-12 2010-08-17 Yale University Detection of survivin in the biological fluids of cancer patients
MXPA03006617A (es) 2001-01-24 2004-12-02 Protein Design Labs Inc Metodos de diagnostico de cancer de pecho, composiciones y metodos de rastreo de moduladores de cancer de pecho.
IL157872A0 (en) 2001-03-12 2004-03-28 Monogen Inc A panel for detecting a generic disease state containing a plurality of probes and using cell-based diagnosis
DK1410011T3 (da) 2001-06-18 2011-07-18 Netherlands Cancer Inst Diagnose og prognose for brystcancerpatienter
US7125680B2 (en) 2001-07-27 2006-10-24 The Regents Of The University Of California Methods and materials for characterizing and modulating interaction between heregulin and HER3
AU2002343443A1 (en) 2001-09-28 2003-04-14 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
US6964850B2 (en) * 2001-11-09 2005-11-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US20030198972A1 (en) * 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
EP2261368A1 (fr) 2002-03-13 2010-12-15 Genomic Health, Inc. Profilage de l'expression génétique dans des tissus de tumeurs prélevées par biopsie
AU2003215460A1 (en) 2002-03-28 2003-10-13 Qlt Inc. Cancer associated protein kinases and their uses
EP1900827A3 (fr) 2002-05-21 2008-04-16 Bayer HealthCare AG Procédés et compositions pour la prédiction, le diagnostic, le pronostic et la prévention et le traitement de néoplasies malignes
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP1644858B1 (fr) * 2003-07-10 2017-12-06 Genomic Health, Inc. Algorithme de profile d'expression et test du pronostic du cancer
CA2848463A1 (fr) * 2004-04-09 2005-10-27 Genomic Health, Inc. Marqueurs d'expression genique permettant de predire la reponse a la chimiotherapie

Also Published As

Publication number Publication date
US7622251B2 (en) 2009-11-24
JP4939425B2 (ja) 2012-05-23
AU2005304878A1 (en) 2006-05-18
DK1815014T3 (da) 2012-06-18
US20100184041A1 (en) 2010-07-22
JP2008518620A (ja) 2008-06-05
WO2006052731A3 (fr) 2007-04-19
EP1815014B1 (fr) 2012-03-21
AU2005304878B2 (en) 2010-07-08
IL182930A0 (en) 2007-09-20
ES2384107T3 (es) 2012-06-29
CA2585561C (fr) 2018-07-17
EP1815014A2 (fr) 2007-08-08
ATE550440T1 (de) 2012-04-15
US20060166231A1 (en) 2006-07-27
IL182930A (en) 2013-03-24
WO2006052731A2 (fr) 2006-05-18

Similar Documents

Publication Publication Date Title
AU2005304878B2 (en) Molecular indicators of breast cancer prognosis and prediction of treatment response
US7930104B2 (en) Predicting response to chemotherapy using gene expression markers
AU2004258085B2 (en) Expression profile algorithm and test for cancer prognosis
JP4723472B2 (ja) 乳癌予後診断のための遺伝子発現マーカー
AU2005233593B2 (en) Gene expression markers for predicting response to chemotherapy
HK1254085B (en) Expression profile algorithm and test for prognosing breast cancer recurrence
AU2016210735A1 (en) Gene expression markers for predicting response to chemotherapy

Legal Events

Date Code Title Description
EEER Examination request